Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 9

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 9
---
 of May 25, 2022 (the “ATM Agreement”) with
H.C. Wainwright & Co., LLC (“Wainwright”) as sales agent. Pursuant to the terms of the amended ATM Agreement, the Company
may offer and sell, from time to time, through Wainwright, shares of the Company’s common stock having an aggregate offering price
of up to $5,500,000. The Company intends to use the net proceeds from any offering under the amended ATM Agreement for general corporate
purposes, including research and development activities, capital expenditures and working capital.

On
July 30, 2024, the Company notified Wainwright that it was suspending its use of and terminating the “at the market offering”
sales agreement prospectus (the “ATM Prospectus”), related to the potential issuance from time to time of the Company’s
common stock pursuant to the ATM Agreement, by and between the Company and Wainwright. Notwithstanding the termination of the ATM Prospectus,
the ATM Agreement remains in full force and effect.

On
September 3, 2024, the Company filed a new prospectus supplement to the 2024 Registration Statement with the SEC for an aggregate offering
price of up to $5,500,000 related to the potential issuance from time to time of the Company’s common stock pursuant to the ATM
Agreement with Wainwright as sales agent.

On
July 22, 2025, the Company filed a prospectus supplement (the “Prospectus Supplement”) to register an additional $4,500,000
of shares of the Company’s common stock, par value $0.01 per share issuable pursuant to the At the Market Offering Agreement, dated
as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales
Agreement”), by and between the Company and H.C. Wainwright & Co., LLC, as sales agent or principal (the “Sales Agent”).
The Company previously registered the offer and sale of up to $5,500,000 of shares of Common Stock through the Sales Agent under the
Sales Agreement. Prior to the date hereof, the Company has sold an aggregate of $1,815,267 shares of Common Stock through the Sales Agent
under the Sales Agreement. Accordingly, the Prospectus Supplement covers an aggregate of $8